Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 10:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Diagnosis of Melanoma Clear all
Completed Phase 3 Interventional Results available

A Study of Vemurafenib Adjuvant Therapy in Participants With Surgically Resected Cutaneous BRAF-Mutant Melanoma

NCT01667419
View directory record Official record
Conditions
Melanoma
Interventions
Vemurafenib, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
498 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
47
States / cities
Birmingham, Alabama • California City, California • Hayward, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2019 · Synced Jul 23, 2026, 10:27 PM EDT
Completed Phase 1 Interventional Results available

PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma

NCT01621490
View directory record Official record
Conditions
Advanced Melanoma, Metastatic Melanoma
Interventions
Nivolumab, Ipilimumab
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
12
States / cities
Los Angeles, California • Chicago, Illinois • Lutherville, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2024 · Synced Jul 23, 2026, 10:27 PM EDT
Withdrawn No phase listed Observational

Autonomic Phenotype Before and After Akt Inhibition

NCT01593579
View directory record Official record
Conditions
Diagnosis of Melanoma
Interventions
Autonomic Function Tests, supine and standing catecholamines
Behavioral · Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 22, 2014 · Synced Jul 23, 2026, 10:27 PM EDT
Completed Phase 2 Interventional

Vaccine Biotherapy of Cancer: Autologous Tumor Cells and Dendritic Cells

NCT00948480
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
Autologous tumor cells plus dendritic cells, GM-CSF
Biological · Drug
Lead sponsor
Hoag Memorial Hospital Presbyterian
Other
Eligibility
16 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Jul 14, 2016 · Synced Jul 23, 2026, 10:27 PM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Tesetaxel in Metastatic Melanoma

NCT01064713
View directory record Official record
Conditions
Advanced Melanoma, Cancer
Interventions
Tesetaxel
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2018 · Synced Jul 23, 2026, 10:27 PM EDT
Terminated Phase 2 Interventional Results available

Interleukin-2 in Metastatic Melanoma

NCT01702896
View directory record Official record
Conditions
Melanoma Metastatic
Interventions
Interleukin-2
Drug
Lead sponsor
Western Regional Medical Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Goodyear, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 4, 2018 · Synced Jul 23, 2026, 10:27 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Cell Therapy for Metastatic Melanoma Using CD8 Enriched Tumor Infiltrating Lymphocytes

NCT01236573
View directory record Official record
Conditions
Skin Cancer, Metastatic Melanoma
Interventions
Fludarabine, Cyclophosphamide, IL-12 transduced TIL
Drug · Biological
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 66 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 25, 2015 · Synced Jul 23, 2026, 10:27 PM EDT
Terminated Phase 1 Interventional

A Study of SGN-CD228A in Advanced Solid Tumors

NCT04042480
View directory record Official record
Conditions
Cutaneous Melanoma, Pleural Mesothelioma, HER2 Negative Breast Neoplasms, Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
Interventions
SGN-CD228A
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
10
States / cities
Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2023 · Synced Jul 23, 2026, 10:27 PM EDT
Completed Phase 1 Interventional

Thalidomide and Docetaxel in Treating Patients With Advanced Cancer

NCT00049296
View directory record Official record
Conditions
Cancer
Interventions
docetaxel, thalidomide
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 10, 2010 · Synced Jul 23, 2026, 10:27 PM EDT
Recruiting Phase 2 Interventional

GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma

NCT05913388
View directory record Official record
Conditions
Metastatic Melanoma, Head and Neck Squamous Cell Carcinoma
Interventions
GB1211, Pembrolizumab, Placebo
Drug
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Jul 23, 2026, 10:27 PM EDT
Completed Phase 1 Interventional Results available

Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors

NCT03864042
View directory record Official record
Conditions
Advanced Solid Tumors, Metastatic Melanoma
Interventions
losartan, dextromethorphan, caffeine, omeprazole, midazolam, rosuvastatin, bupropion immediate release (IR), encorafenib, binimetinib, modafinil
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
11
States / cities
Orange, California • Aurora, Colorado • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2024 · Synced Jul 23, 2026, 10:27 PM EDT
Completed Phase 1 Interventional

Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone

NCT02027961
View directory record Official record
Conditions
Melanoma
Interventions
Durvalumab, Dabrafenib, Trametinib
Biological · Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
7
States / cities
Scottsdale, Arizona • Los Angeles, California • San Francisco, California + 4 more
Source: ClinicalTrials.gov public record
Updated May 16, 2019 · Synced Jul 23, 2026, 10:27 PM EDT
Terminated Phase 1 Interventional

Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides

NCT02890368
View directory record Official record
Conditions
Solid Tumors, Mycosis Fungoides, Melanoma, Merkel-cell Carcinoma, Squamous Cell Carcinoma, Breast Carcinoma, Human Papillomavirus-Related Malignant Neoplasm, Soft Tissue Sarcoma
Interventions
TTI-621 Monotherapy, TTI-621 + PD-1/PD-L1 Inhibitor, TTI-621 + pegylated interferon-α2a, TTI-621 + T-Vec, TTI-621 + radiation
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
7
States / cities
Duarte, California • New York, New York • Portland, Oregon + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2023 · Synced Jul 23, 2026, 10:27 PM EDT
Completed Phase 1 Interventional

Targeted Imaging of Melanoma for Alpha-Particle Radiotherapy

NCT04904120
View directory record Official record
Conditions
Melanoma (Skin), Melanoma Stage IV, Melanoma, Uveal, Melanoma, Mucosal
Interventions
[203Pb]VMT01, [68Ga]VMT02
Drug
Lead sponsor
Perspective Therapeutics
Industry
Eligibility
18 Years to 89 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 6, 2023 · Synced Jul 23, 2026, 10:27 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients

NCT02009397
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
Ipilimumab, GM-CSF
Drug
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Nov 21, 2021 · Synced Jul 23, 2026, 10:27 PM EDT
Completed Phase 1 Interventional Results available

A Study of the Effect of Food on the Pharmacokinetics of Single Dose RO5185426 And the Safety And Efficacy of Continuous Administration in Patients With BRAF V600E Mutation-Positive Metastatic Melanoma

NCT01264380
View directory record Official record
Conditions
Malignant Melanoma
Interventions
RO5185426
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
10
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Jul 23, 2026, 10:27 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study in Subjects With Small Primary Choroidal Melanoma

NCT03052127
View directory record Official record
Conditions
Uveal Melanoma, Ocular Melanoma, Choroidal Melanoma
Interventions
Light-activated AU-011, Laser Activation
Drug · Device
Lead sponsor
Aura Biosciences
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
13
States / cities
Tucson, Arizona • Los Angeles, California • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2024 · Synced Jul 23, 2026, 10:27 PM EDT
Completed Phase 2 Interventional Results available

Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma

NCT00976573
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
bevacizumab, carboplatin, everolimus, paclitaxel
Biological · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
310
States / cities
Scottsdale, Arizona • Martinez, California • Mountain View, California + 214 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2017 · Synced Jul 23, 2026, 10:27 PM EDT
Terminated Phase 2 Interventional Results available

Anti-gp100 Cells Plus ALVAC gp100 Vaccine to Treat Advanced Melanoma

NCT00610311
View directory record Official record
Conditions
Metastatic Melanoma, Skin Cancer
Interventions
cyclophosphamide, fludarabine phosphate, Aldesleukin, ALVAC gp100 Vaccine, anti-gp100:154-162 Tcell receptor (TCR) peripheral blood lymphocyte (PBL)
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 27, 2015 · Synced Jul 23, 2026, 10:27 PM EDT
Completed Phase 1 Interventional

Safety Study Using Photodynamic Therapy Light Therapy for Patients With Chest Wall Progression of Breast Cancer and Satellite Metastases of Melanoma

NCT00862901
View directory record Official record
Conditions
Breast Cancer, Skin Cancer
Interventions
CLIPT patch
Device
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 25, 2011 · Synced Jul 23, 2026, 10:27 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors

NCT03361228
View directory record Official record
Conditions
Solid Tumors
Interventions
INCB001158, Epacadostat, Pembrolizumab
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Birmingham, Alabama • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 20, 2020 · Synced Jul 23, 2026, 10:27 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)

NCT02554812
View directory record Official record
Conditions
Advanced Cancer
Interventions
Avelumab, Utomilumab, PF-04518600, PD 0360324, CMP-001
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
409 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
57
States / cities
Encinitas, California • La Jolla, California • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2024 · Synced Jul 23, 2026, 10:27 PM EDT
Recruiting Phase 1Phase 2 Interventional

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

NCT04851119
View directory record Official record
Conditions
Colorectal Carcinoma, Endometrial Carcinoma, Melanoma, Neuroblastoma, Ovarian Carcinoma, Pancreatic Ductal Adenocarcinoma, Recurrent Desmoid Fibromatosis, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Hepatocellular Carcinoma, Recurrent Malignant Solid Neoplasm, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Refractory Desmoid Fibromatosis, Refractory Ewing Sarcoma, Refractory Hepatoblastoma, Refractory Hepatocellular Carcinoma, Refractory Malignant Solid Neoplasm, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Solid Pseudopapillary Neoplasm of the Pancreas, Wilms Tumor
Interventions
Biospecimen Collection, Dual X-ray Absorptiometry, Tegavivint, X-Ray Imaging
Procedure · Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
12 Months to 30 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
21
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 18 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Jul 23, 2026, 10:27 PM EDT
Active, not recruiting Not applicable Interventional

Proton Pencil Beam Scanning GRID for Treatment of Bulky Tumors

NCT05121545
View directory record Official record
Conditions
Sarcoma, Melanoma
Interventions
Pro-GRID
Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Jul 23, 2026, 10:27 PM EDT